SCHEMBL3695465

SCHEMBL3695465

CNC(=O)c1cc(Sc2ccc(Cl)nc2)n(-c2ccccc2C)n1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 5/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 2/20 0.39
BRD4 O60885 2/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
BAZ2B Q9UIF8 1/20 0.36
NPY5R Q15761 2/20 0.36
DHODH Q02127 2/20 0.36
PTGER1 P34995 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
LMNA P02545 1/20 0.34
NTRK1 P04629 2/20 0.34
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2840457 0.91 MALT1 (0.40) MALT1MEN1KMT2ABRD4NFKB1
SCHEMBL3702208 0.90 MALT1 (0.35) MALT1MEN1KMT2ABRD4NFKB1
SCHEMBL3694760 0.89 MALT1 (0.39) MALT1MEN1KMT2ABRD4NFKB1
SCHEMBL3702068 0.87 KCNQ3 (0.39) MALT1MEN1KMT2ANFKB1NFKB2
SCHEMBL3694848 0.86 SCN9A (0.41) MALT1MEN1KMT2ANFKB1NFKB2
SCHEMBL3691798 0.85 KCNQ3 (0.37) MALT1MEN1KMT2ABRD4NFKB1
SCHEMBL3694274 0.85 NTRK1 (0.36) MALT1MEN1KMT2ABRD4NFKB1
SCHEMBL3693337 0.84 MAPT (0.42) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL3694337 0.83 MALT1 (0.35) MALT1MEN1KMT2ANFKB1NFKB2
SCHEMBL3698170 0.83 MALT1 (0.38) MALT1MEN1KMT2ANFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
EP-2190822-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-06-02 EP disclosed
WO-2009041705-A9 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2009-08-13 WO disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2009041705-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 MALT1 3172/4885MEN1 1910/4885KMT2A 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.